Iconic Therapeutics Secures $40,000,000 Series C Financing Round

  • Feed Type
  • Date
  • Company Name
    Iconic Therapeutics
  • Mailing Address
    395 Oyster Point Boulevard South San Francisco, CA 94080 USA
  • Company Description
    Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines. Our deep understanding of the role of Tissue Factor (TF) in angiogenesis, inflammation, and metastasis has led us to develop a new approach to retinal disease and cancer. Our lead product candidate, ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of acute vision loss in AMD.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    Proceeds from the financing will be used to advance development of lead molecule ICON-1 in retinal diseases as well as begin clinical trials in ocular melanoma, Iconic’s first oncology indication. With new capital, Iconic expects to continue to add key talent to advance and expand the broad opportunities that may be addressed with a Tissue Factor-based approach.
  • M&A Terms
  • Venture Investor
    HBM BioCapital
  • Venture Investor
    Cormorant Asset Management
  • Venture Investor
    Osage Partners
  • Venture Investor
    MPM Capital
  • Venture Investor
    H.I.G. Capital
  • Venture Investor
    Lundbeckfond Ventures

Trending on Xconomy